Back to top
more

bioMerieux (BMXMF)

(Delayed Data from OTC)

$105.00 USD

105.00
NA

+1.83 (1.77%)

Updated Apr 19, 2024 09:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BMXMF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for bioMerieux falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents -99,999 582 951 445 308
Receivables NA 977 900 834 749
Notes Receivable NA 0 0 0 0
Inventories NA 777 751 619 554
Other Current Assets NA 0 9 0 0
Total Current Assets NA 2,336 2,611 1,898 1,611
Net Property & Equipment NA 1,317 1,302 1,073 1,002
Investments & Advances NA 96 73 58 47
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 62 34 83 111
Intangibles NA 1,515 1,279 1,211 1,300
Deposits & Other Assets NA 14 15 16 18
Total Assets NA 5,465 5,462 4,487 4,236
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable NA 0 0 0 0
Accounts Payable NA 284 283 237 237
Current Portion Long-Term Debt NA 197 118 147 491
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 52 80 51 36
Other Current Liabilities NA 659 650 621 546
Total Current Liabilities NA 1,192 1,131 1,055 1,311
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 56 72 121 158
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 335 429 403 172
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 43 74 74 70
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,626 1,706 1,652 1,711
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 13 14 14 13
Capital Surplus NA 3,308 2,970 2,302 2,149
Retained Earnings NA 477 711 462 306
Other Equity NA 41 61 57 57
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 3,838 3,756 2,834 2,525
Total Liabilities & Shareholder's Equity NA 5,465 5,462 4,487 4,236
Total Common Equity 0 3,838 3,756 2,834 2,525
Shares Outstanding 118.30 118.30 118.30 118.30 118.30
Book Value Per Share 0.00 32.44 31.75 23.96 21.35

Fiscal Year End for bioMerieux falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 -99,999 -99,999 -99,538 -99,999
Receivables NA NA NA 969 NA
Notes Receivable NA NA NA NA NA
Inventories NA NA NA 917 NA
Other Current Assets NA NA NA NA NA
Total Current Assets NA NA NA 2,347 NA
Net Property & Equipment NA NA NA 1,383 NA
Investments & Advances NA NA NA 97 NA
Other Non-Current Assets NA NA NA NA NA
Deferred Charges NA NA NA 68 NA
Intangibles NA NA NA 1,447 NA
Deposits & Other Assets NA NA NA 8 NA
Total Assets NA NA NA 5,486 NA
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA NA NA NA NA
Accounts Payable NA NA NA 266 NA
Current Portion Long-Term Debt NA NA NA 175 NA
Current Portion Capital Leases NA NA NA NA NA
Accrued Expenses NA NA NA NA NA
Income Taxes Payable NA NA NA 44 NA
Other Current Liabilities NA NA NA 584 NA
Total Current Liabilities NA NA NA 1,069 NA
Mortgages NA NA NA NA NA
Deferred Taxes/Income NA NA NA 37 NA
Convertible Debt NA NA NA NA NA
Long-Term Debt NA NA NA 360 NA
Non-Current Capital Leases NA NA NA NA NA
Other Non-Current Liabilities NA NA 49 NA
Minority Interest (Liabilities) NA NA NA NA NA
Total Liabilities NA NA NA 1,515 NA
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA NA NA NA NA
Common Stock (Par) NA NA NA 13 NA
Capital Surplus NA NA NA 3,766 NA
Retained Earnings NA NA NA 176 NA
Other Equity NA NA NA 15 NA
Treasury Stock NA NA NA NA NA
Total Shareholder's Equity NA NA NA 3,971 NA
Total Liabilities & Shareholder's Equity NA NA NA 5,486 NA
Total Common Equity 0 0 0 103,970 0
Shares Outstanding NA 118.30 118.30 118.30 118.30
Book Value Per Share 0.00 0.00 0.00 878.86 0.00